21324-31-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol is used as a reactant in the synthesis of 2,9-disubstituted-N6-(arylcarbamoyl)-8-azaadenines. These synthesized compounds serve as new selective A3 adenosine receptor antagonists, which have potential applications in the treatment of various diseases and conditions, such as cancer, neurodegenerative disorders, and inflammatory diseases.
Used in Biochemical and Molecular Modeling Studies:
In addition to its role in the pharmaceutical industry, 3-Benzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol is also utilized in biochemical and molecular modeling studies. These studies aim to understand the interactions between the compound and its target molecules, such as proteins and enzymes, which can provide valuable insights into the development of new drugs and therapies.

InChI:InChI=1/C11H9N5O/c17-11-9-10(12-7-13-11)16(15-14-9)6-8-4-2-1-3-5-8/h1-5,7,15H,6H2

Upstream product

• 109-94-4 formic acid ethyl ester 
• 100-46-9 benzylamine 
• 15948-97-7 N⁴-benzyl-6-chloropyrimidine-4,5-diamine 
• 4342-08-9 4-amino-3-benzyl-1,2,3-triazole-5-carboxamide 
• 77287-34-4 formamide 
• 126537-91-5 5-amino-1-benzyl-1H-[1,2,3]triazole-4-carboxylic acid phenylamide 
• 622-79-7 benzyl azide 
• 100-39-0 benzyl bromide 

Downstream Products

• 21410-06-0 3-benzyl-7-chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 13925-58-1 9-benzyl-8-azaadenine 

Relevant academic research and scientific papers

Cytoprotective activities of kinetin purine isosteres

Kinetin (N6-furfuryladenine), a plant growth substance of the cytokinin family, has been shown to modulate aging and various age-related conditions in animal models. Here we report the synthesis of kinetin isosteres with the purine ring replace

1,2,3-Triazole fused with pyridine/pyrimidine as new template for antimicrobial agents: Regioselective synthesis and identification of potent N-heteroarenes

The 1,2,3-triazole ring fused with pyridine/pyrimidine was explored as new template for the identification of potential antimicrobial agents. The regioselective synthesis of these pre-designed N-heteroarenes was achieved via exploring the application of Buchwald's strategy (i.e. C–N bond formation/reduction/diazotization/cyclization sequence) to the N-heteroarene system. Two of them showed promising antibacterial (comparable to streptomycin) and several showed potent antifungal (comparable to mancozeb) activities.

2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies

A number of N6-(N-arylcarbamoyl)-2-substituted-9-benzyl-8- azaadenines, obtained by a modification of the synthetic scheme used to prepare selective A1 ligands, by only three or two steps, are described. At first we prepared a series

Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation

The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidases-related diseases and disorders and inhibition of platelet activation.

Synthesis of 6-mono- and 5,6-disubstituted 1,2,3-triazolo[4,5-d]pyrimidin- 7-ones

The reactions of N-substituted 4-amino-3-benzyl-1,2,3-triazole-5- carboxamides with phosphorus oxochloride and dimethylformamide at 80°C or with triethyl orthoacetate and acetic anhydride at 160°C afforded 6-mono- or 5,6-disubstituted 1,2,3-triazolo[4.5-d